1
|
Meng G, Wang J, Huang J, Wang Y, Wei N, Wang Z. Successful Outcome of a Case of Acute Myeloid Leukemia with t(8;21)/AML-ETO Following Langerhans Cell Histiocytosis. Turk J Haematol 2019; 36:294-296. [PMID: 31284703 PMCID: PMC6863017 DOI: 10.4274/tjh.galenos.2019.2019.0126] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Affiliation(s)
- Guangqiang Meng
- Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Jingshi Wang
- Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Jiancheng Huang
- Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Yini Wang
- Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Na Wei
- Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Zhao Wang
- Beijing Friendship Hospital, Capital Medical University, Beijing, China
| |
Collapse
|
2
|
Pina-Oviedo S, Torres-Cabala CA, Miranda RN, Tetzlaff MT, Singh S, Rapini RP, Prieto VG, Aung PP. Concomitant Cutaneous Langerhans Cell Hystiocytosis and Leukemia Cutis. Am J Dermatopathol 2017; 39:388-392. [DOI: 10.1097/dad.0000000000000775] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
Chang NY, Wang J, Wen MC, Lee FY. Langerhans Cell Sarcoma in a Chronic Myelogenous Leukemia Patient Undergoing Imatinib Mesylate Therapy. Int J Surg Pathol 2013; 22:456-63. [DOI: 10.1177/1066896913501382] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Langerhans cell sarcoma (LCS) is a rare malignancy requiring differential diagnosis from other high-grade nonhematologic and hematologic tumors. The pathogenesis of LCS remains unknown. Notably, LCS and its benign counterpart, Langerhans cell histiocytosis (LCH), are frequently associated with other malignancies. To the best of our knowledge, we describe the first case of LCS in a chronic myelogenous leukemia (CML) patient undergoing imatinib mesylate therapy. We performed molecular cytogenetic analyses for investigating the association between LCS and CML. In our case, molecular cytogenetic analysis did not reveal BCR-ABL1 fusion and BRAF V600E mutation, suggesting that LCS may be coincident in this patient. However, recurrent BRAF V600E mutation has been found in LCH. Published reports have revealed the clonal relationship between LCH/LCS and other hematologic malignancies, especially lymphoid neoplasms. However, there are only 2 reports demonstrating the clonal relationship between LCH and myeloid neoplasms. The association of LCH/LCS with myeloid neoplasms and the role of BRAF V600E mutation in LCS are discussed.
Collapse
Affiliation(s)
- Nien-Yi Chang
- Da Chien General Hospital, Miaoli, Taiwan
- Taichung Veterans General Hospital, Tachiung, Taiwan
| | - John Wang
- Taichung Veterans General Hospital, Tachiung, Taiwan
| | - Mei-Chin Wen
- Taichung Veterans General Hospital, Tachiung, Taiwan
| | - Fang-Yi Lee
- Taichung Veterans General Hospital, Tachiung, Taiwan
| |
Collapse
|